By sharing global expertise and collating information, IDDO strengthens knowledge of the scale of the problem of poor quality medicines and the most affected areas, and raises vital awareness among key stakeholders.
Impact of poor quality medicines

Medicines are of vital importance in health systems, and access to quality-assured medicines is part of the basic right to health. Nevertheless, poor quality medical products, including medicines, vaccines and diagnostic devices, are widespread due to poor manufacture (substandard medicines) or deliberate falsification. Poor quality medicines jeopardise national, regional and global attempts to improve access to effective health care because they lead to avoidable morbidity and mortality, waste financial resources, and contribute to drug resistance. 

Medicine Quality & Public Health Conference 2018

Until now, there has never been an opportunity for the diverse stakeholders involved in medicine quality and drug regulation to come together – within the framework of a specific academic conference – to share ideas and expertise, and to outline the coordinated steps that need to be taken to tackle the problem of poor quality medicines on an international scale. Join us for the first-ever dedicated academic and programmatic conference on Medicine Quality and Public Health, 23-28 September at Oxford University.

WWARN's Antimalarial Quality work

WWARN's Medicine Quality Scientific Group is sharing expertise and collating information to increase our understanding of the prevalence and distribution of poor-quality medicines around the world.

WWARN's Antimalarial Quality Surveyor

The Antimalarial Quality Surveyor helps to respond to some of the critical gaps in information. This mapping tool delivers customised summaries of published reports of antimalarial medicine quality across regions and over time.